Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2

McLaughlin, John; Rosen, Barry P.; Moody, Joel; Pal, Tuya; Fan, Isabel; Shaw, Patricia; Risch, Harvey A.; Sellers, Thomas A.; Sun, Ping; Narod, Steven A.

doi:10.1093/jnci/djs494

Cited by 145 publications

(120 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional investigators confirmed the above findings by showing that patients with BRCA mutation-related (hereditary) epithelial ovarian cancer exhibited improved PFS, OS as well as increased sensitivity to platinum agents in the adjuvant setting [18][19][20][21][22][23][24].…”

Section: Brca1 and Brca2mentioning

confidence: 73%

PARP inhibition and synthetic lethality in ovarian cancer

Eskander

Tewari

2014

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

Section: Brca1 and Brca2mentioning

confidence: 73%

PARP inhibition and synthetic lethality in ovarian cancer

Eskander

Tewari

2014

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

“…To ensure that a clinical study is reliable, it is important that most patients be followed for a long period, ideally for 10 or more years. Studies based on shorter follow-up periods (5 years, say) may lead to erroneous conclusions even if the total number of person-years is large-a situation similar to that with ovarian cancer 6,7 . Screening studies and studies involving clinical interventions can both potentially be affected.…”

Section: Discussionmentioning

confidence: 99%

Are Two-Centimeter Breast Cancers Large or Small?

et al. 2013

View full text Add to dashboard Cite

Background: Node-negative breast cancers from 2 cm to 5 cm in size are classified as stage ii, and smaller cancers, as stage i. We sought to determine if the prognosis of women with a breast cancer exactly 2 cm in size more closely resembles that of women with a stage i or a stage ii breast cancer. Methods: Using a cohort of 4265 young women with breast cancer, we compared the 10-year breast cancer mortality rates for women who had a tumour 0.1–1.9 cm, exactly 2.0 cm, and 2.1–2.9 cm. Results: In the first 3 years after diagnosis, the survival pattern of women with a 2.0-cm breast cancer was nearly identical to that of women with a larger cancer (2.1–3.0 cm). From year 3 to year 10, the relative survival of women with a 2.0-cm breast cancer was improved and nearly identical to that of women with a smaller cancer. The 10-year survival rate was 89.3% for women with tumours less than 20 mm, 86.1% for women with tumours equal to 20 mm, and 81.2% for women with 21-mm to 29-mm tumours. Conclusions: For young women with small breast cancers, the relative mortality from breast cancer is dynamic with increasing tumour size and varies with time from diagnosis.

show abstract

“…Following classic tumor suppressor gene kinetics, BRCA1-and BRCA2-induced carcinogenesis result from a "second hit" somatic mutation(s) in the normal allele, leading to loss of BRCA function [21] and homologous DNA recombination deficiency (HRD). This HRD state, though carcinogenic, can paradoxically confer sensitivity to platinum and other DNA-damaging cytotoxics, as well as PARP inhibitors [22,23].Several studies have reported better prognosis for women with BRCA-mutated ovarian cancer, especially BRCA2, possibly secondary to the improved platinum response [22][23][24][25][26][27]. Other genes in the HR pathway such as RAD51C, RAD51D, BRIP1, PALB2, and BARD1, may also influence ovarian cancer risk and biology [28][29][30].…”

Section: The Importance Of Genetic Testing In Cancer Care Deliverymentioning

confidence: 99%